Genitourinary Cancers | Specialty

Treatment Landscape of Advanced Renal Cell Carcinoma

October 15th 2020

Expert Perspectives in the Evolving Treatment Landscape for Metastatic Renal Cell Carcinoma

October 14th 2020

Robert J. Motzer, MD, and Ulka Nitin Vaishampayan, MD, MBBS, FAB, discuss some of the latest updates in metastatic renal cell carcinoma.

Dr. Farrington on the Importance of Genetic Testing in CRC

October 13th 2020

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

Updates in Relapsed/Refractory Metastatic Renal Cell Carcinoma

October 13th 2020

Targeted therapy and immunotherapy have improved survival outcomes for patients with metastatic renal cell carcinoma.

Dr. Bakouny on the Rate of Disease Progression in Sarcomatoid Carcinoma

October 12th 2020

Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.

Enfortumab Vedotin Demonstrates Durable Responses in Advanced Urothelial Cancer

October 12th 2020

Enfortumab vedotin elicited durable responses in patients with locally advanced or metastatic urothelial cancer who received previous treatment with a PD-1/PD-L1 inhibitor, have not been given a platinum-containing chemotherapy, and are not eligible for cisplatin.

Immunomedics Acquisition Transfers Development of Sacituzumab Govitecan to Gilead Sciences

October 8th 2020

Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.

Choueiri Highlights Efficacy of Cabozantinib/Nivolumab in RCC, Next Steps for Research

October 7th 2020

Toni Choueiri, MD, discusses the CheckMate-9ER trial, the next steps for nivolumab/cabozantinib, and other cabozantinib regimens under exploration.

Nivolumab/Ipilimumab Elicits Durable Responses in Refractory Advanced RCC

October 6th 2020

Scott Tykodi, MD, PhD, discusses the FRACTION-RCC study and other novel combinations under exploration for heavily pretreated patients with advanced renal cell carcinoma.

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCC

October 1st 2020

Sumanta K. Pal, MD, discusses the safety profile of cabozantinib in combination with atezolizumab in advanced renal cell carcinoma.

Dr. Shah on the Rationale for the KEYNOTE-590 Trial in Esophageal Carcinoma

September 30th 2020

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in ​locally advanced or metastatic esophageal carcinoma.

Adjuvant Nivolumab Improves DFS in High-Risk Muscle-Invasive Urothelial Carcinoma

September 25th 2020

Adjuvant nivolumab was found to result in a significant improvement in disease-free survival compared with placebo in patients with high-risk muscle-invasive urothelial carcinoma, including those whose tumors expressed PD-L1 of 1% or higher, meeting the primary end points of the phase 3 CheckMate-274 trial.

Experts Call for Increased Awareness of Existing Racial Disparities in RCC, Other Malignancies

September 24th 2020

Despite the numerous reports detailing racial differences in cancer outcomes and care over the years, the reasons underlying these disparities continue to be under deep exploration.

Study Demonstrates Improved Responses With Molecularly-Guided Therapy in mRCC

September 21st 2020

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

Cabozantinib Combo Induces Clinical Activity in Advanced ccRCC

September 21st 2020

Treatment with cabozantinib in combination with atezolizumab demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma.

Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma

September 20th 2020

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

Sacituzumab Govitecan Shows Sustained Activity in Heavily Pretreated Metastatic Urothelial Carcinoma

September 19th 2020

Sacituzumab govitecan-hziy continued to showcase significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.

Urothelial Cancer Treatment Combination Fails To Meet OS End Points

September 19th 2020

Neither monotherapy with durvalumab or combination treatment with durvalumab plus tremelimumab met co-primary end points of overall survival vs chemotherapy for the treatment of metastatic urothelial cancer.

Nivolumab/Ipilimumab Combo Shows Durable Benefit at 4 Years in Advanced RCC

September 19th 2020

The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.

Nivolumab/Cabozantinib Combo Doubles PFS in Frontline RCC

September 19th 2020

The combination of nivolumab and cabozantinib led to a 49% reduction in the risk of disease progression or death, while also significantly improving overall survival and doubling objective response rate, compared with sunitinib in the first-line treatment of patients with advanced renal cell carcinoma.